An interventional study of Lungpacer PROTECT Diaphragm Pacing Therapy in Acute Respiratory Distress Syndrome and Ventilation Therapy; Complications, sponsored by Lungpacer Medical Inc.. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-05.
Sponsored by Lungpacer Medical Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 217 studies in Respiratory Distress Syndrome with a site in France — 41 open to participants now, 43 under way, 7 of them phase 3. Respiratory Distress Syndrome · France.
Among the 217 studies in Respiratory Distress Syndrome with a site in France, this one is the 99th largest by enrollment of the 118 interventional ones that give a count, is one of 16 that started in 2021, is one of 77 with no phase, and was the 147th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →41 of the 217 studies in Respiratory Distress Syndrome with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages up to 17
Centre Hospitalier de la côte Basque · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 26 · Phase 4 5
First in 2002; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 50 across the 118 interventional studies, 80 across the 97 observational. Of the 145 that completed or were terminated, 4 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 217 have an industry lead sponsor. The 10 most frequent:
Lungpacer Medical Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Lungpacer Medical Inc. has 1 study filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
12 of the studies in Respiratory Distress Syndrome with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03368092Phase 3University Hospital, Strasbourg, FranceInhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma | 2027-09-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06254313University Hospital, BordeauxThe Role of Cxcr4Hi neutrOPhils in InflueNza | 2026-12 |
| NCT06119516Assistance Publique - Hôpitaux de ParisTranspulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study. | 2027-04-04 |
| NCT06807983University Hospital, ToulouseLUng and Cardiac Ultrasound for REspiratory Distress in ElDerly | 2027-05-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 217 studies in Respiratory Distress Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Lungpacer PROTECT Diaphragm Pacing Therapy System (DPTS) is a temporary, percutaneously-placed, transvenous, phrenic nerve-stimulating device intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients. The purpose of the PROTECT DPTS is to improve gas exchange, regional lung ventilation, and hemodynamics, and decrease atelectasis in patients presenting with acute respiratory distress syndrome (ARDS).
The PIRAT clinical study is intended to assess the feasibility, safety and effectiveness of transvenous phrenic-nerve-stimulating diaphragm pacing on clinical outcomes in mechanically ventilated patients. By delivering electrical stimulation to the phrenic nerves, which in turn causes the diaphragm muscle to contract, the PROTECT DPTS is intended to protect the diaphragm from atrophy and preserve lung mechanics to reduce lung inflammation and injury associated with short-term mechanical ventilation. Sustained lung and diaphragm health during early mechanical ventilation is expected to reduce the risk of comorbidities, improve clinical outcomes such as weaning success, and thereby reduce the number of patients who require prolonged mechanical ventilation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Lungpacer PROTECT Diaphragm Pacing Therapy
PROTECT diaphragm pacing therapy is intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients.
Also known as: Lungpacer PROTECT DPTS
Changes in PaO2/FiO2 ratio
The changes in PaO2/FiO2 ratio during each acute standard of care ventilation and acute PROTECT pacing therapy session.
Time frame: Day 1
Successful LIVE catheter placement
LIVE Catheter was successfully inserted into the left subclavian vein, positioned in accordance with the LIVE Catheter IFU, and the diaphragm was stimulated.
Time frame: Day 1
Alveolar-arterial (A-a) gradient
Alveolar-arterial (A-a) gradient documenting gas exchange during each acute standard of care ventilation and acute PROTECT pacing therapy session.
Time frame: Day 1
Cardiac output index
Pulse contour cardiac output index assessed by transpulmonary thermodilution during each acute standard of care ventilation and acute PROTECT pacing therapy session.
Time frame: Day 1
Regional lung ventilation
Regional lung ventilation assessed using electrical impedance tomography during each acute standard of care ventilation and acute PROTECT pacing therapy session.
Time frame: Day 1
Regional lung atelectasis
Regional lung atelectasis assessed using electrical impedance tomography during each acute standard of care ventilation and acute PROTECT pacing therapy session.
Time frame: Day 1
Serious adverse events
Occurrence of pneumothorax, significant bleeding and desaturation serious adverse events.
Time frame: Day 5
Days until successful weaning
Time frame: Day 5
Mortality
Time frame: Day 5
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2021 to primary completion in Feb 2023, 17 months.
Of 273 interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
Lungpacer Medical Inc.